<原著>Photographic Subtraction法を応用した唾液腺造影像の検討

Photographic subtraction used in the examination of salivary glands was compared with conventional sialography. Subtraction images obtained from the duct system of parotid grands demonstrated the same images as were obtained by conventional sialography. In duct system of the submaxillary glands, however, the conventional sialograms were clearer than those images obtained by subtraction procedures. Subtraction images could provide the outward form of salivary glands, especially in the parotid glands. In most cases, sialography with subtraction provides valuable imformations in diagnosing salivary gland diseases. But, the results showed that the necessity of applying this modality must be examined carefully

Development of phenology model for evaluation of growing season of understory vegetation in an open-canopy black spruce forest in Alaska

第7回極域科学シンポジウム:[OM] 極域気水圏11月29日（火）国立極地研究所 1階 アトリウ

Detection of spatio-temporal variability of plant phenology around the arctic region by in site and satellite observations

第4回極域科学シンポジウム横断セッション：[IA] 「急変する北極気候システム及びその全球的な影響の総合的解明」―GRENE北極気候変動研究事業研究成果報告2013―11月12日（火） 国立極地研究所 ２階大会議

Total androgen blockade for prostate cancer

前立腺癌の初期治療としてTAB療法は, 従来の内分泌療法と比較してほぼ同等の有効率がえられ, 副作用の出現頻度は女性ホルモン剤に比較し低かった.TAB療法中の再燃の際にはwithdrawal syndromeを考慮する必要があるTo evaluate the usefulness of total androgen blockade (TAB) therapy, we retrospectively studied 45 patients with prostate cancer who received TAB therapy as the first-line treatment. The clinical stage was A2 in 1 patient, B1 in 10, B2 in 9, C in 6, D1 in 3 and D2 in 16. Seven, 25 and 13 patients had well, moderately and poorly differentiated adenocarcinomas, respectively. The patients were placed on 1 of 3 TAB regimens: Luteinizing hormone-releasing hormone (LH-RH) agonist and flutamide (group 1), LH-RH agonist and chlormadinone acetate (group 2) and a surgical castration and flutamide (or chlormadinone acetate) (group 3). The therapeutic effect was evaluated at 12 weeks according to the response criteria in the general rules for clinical and pathological studies on prostatic cancer. The overall response was partial response (PR) in 35 patients (77.8%), no change (NC) in 6 (13.3%) and progressive disease (PD) in 4 (8.9%). PR was obtained in 81.3, 79.2 and 60% of the patients in groups 1, 2 and 3, respectively. One patient with PD responded briefly to flutamide withdrawal. None of the patients developed any severe adverse effects. In conclusion, the first-line TAB therapy is effective for prostate cancer with a lower risk than estrogens. Relapsed cases should be followed for flutamide withdrawal syndrome during TAB therapy